U.S. markets open in 3 hours 57 minutes

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
15.42-0.58 (-3.66%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close16.00
Open16.11
Bid14.22 x 1100
Ask20.00 x 1200
Day's Range14.85 - 16.37
52 Week Range2.47 - 17.11
Volume546,552
Avg. Volume830,389
Market Cap1.969B
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.05
Earnings DateMar 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Organogenesis Appoints David C. Francisco as Chief Financial Officer
    GlobeNewswire

    Organogenesis Appoints David C. Francisco as Chief Financial Officer

    CANTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announces the appointment of David C. Francisco as the Company’s Chief Financial Officer, effective February 15, 2021. In connection with the hiring of Mr. Francisco, Henry Hagopian will serve as the Company’s Senior Vice President of Finance and Treasurer. “I am pleased to welcome Dave to the Organogenesis executive leadership team,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “Dave brings strong strategic, financial, and operational leadership across multiple business areas and over 25 years of finance and accounting experience. I look forward to working with Dave as we continue to execute on our strategy to drive growth and improve profitability while delivering on our mission to substantially improve medical outcomes and lower the overall cost of care.” Prior to joining Organogenesis, Mr. Francisco spent 20 years at PerkinElmer, Inc. (NYSE: PKI), a leading provider of products, services and solutions for the diagnostics, life sciences and applied markets with over $3.5 billion in revenue, where he most recently served as Vice President and Treasurer. During his tenure at PKI, he held a series of leadership roles of increasing responsibility across multiple business areas, including as Vice President, Investor Relations and Vice President of Financial Operations as well as Chief Financial Officer of its Human Health segment which generated $1.4 billion in annual revenue. “Organogenesis is an impressive organization with compelling growth opportunities,” said David Francisco. “I am excited to join the Company at a time that I believe represents an important inflection point in its history and look forward to partnering with Gary and the rest of the executive leadership team to deliver strong operational and financial performance.” Mr. Francisco holds a Bachelor of Science degree in Industrial Engineering & Operations Research from the University of Massachusetts, Amherst, as well as an MBA from the McCallum Graduate School of Business at Bentley University. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Organogenesis Holdings’ expected growth opportunities and strategy to deliver strong growth and improving profitability, that involve a number of risks and uncertainties. Statements that are not historical facts are based on Organogenesis Holdings’ current expectations, beliefs and assumptions. There can be no assurance that Organogenesis Holdings will grow or improve its profitability. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include, but are not limited to: (1) the Company has incurred significant losses since inception and may incur losses in the future; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the impact of any changes to the reimbursement levels for the Company’s products and the impact to the Company of the loss of preferred “pass through” status for PuraPly AM and PuraPly on October 1, 2020; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to complete the relaunch of Affinity and to maintain production in sufficient quantities to meet demand; (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; and (11) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2019 and its subsequently filed periodic reports. Organogenesis Holdings cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Organogenesis Holdings undertakes no obligations to update or revise these statements, except as may be required by law. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. CONTACT: Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis Lori Freedman Lfreedman@organo.com

  • Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March
    GlobeNewswire

    Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

    CANTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences: The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Management will participate in a virtual fireside chat on Thursday, February 18 at 1:00 p.m. Eastern Time. The SVBLeerink 10th Annual Global Healthcare Conference Management will participate in a virtual fireside chat on Wednesday, February 24 at 8:40 a.m. Eastern Time. The Oppenheimer 31st Annual Healthcare Conference Management will present on Wednesday, March 17 at 10:40am Eastern Time. Live audio webcasts of the conference presentations will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website www.organogenesis.com. Archives of the webcasts will be available for replay following the conference for approximately 30 days. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com. Investor Inquiries:Westwicke PartnersMike Piccinino, CFAOrganoIR@westwicke.com Press and Media Inquiries:OrganogenesisLori FreedmanLfreedman@organo.com

  • Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021
    GlobeNewswire

    Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021

    CANTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2020 financial results will be reported after the market closes on Tuesday, March 16. Management will host a conference call at 5:00 p.m. Eastern Time on March 16 to discuss the results of the quarter and the fiscal year, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 6766924. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com. For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 6766924. The webcast will be archived at investors.organogenesis.com. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com. CONTACT: Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis Lori Freedman lfreedman@organo.com